ASX-listed AVITA Medicals jumps most in 3-1/2 months on U.S. FDA nod

AVITA Medical

18/02/2022 03:58

** ASX listed shares of the California, United States-based
medical technology firm  AVH.AX  jump as much as 8.4% to
A$2.700, set for their biggest pct gain since Nov. 4 
    ** Co says the U.S. Food and Drug Administration (FDA) has
reviewed and approved the premarket approval application for
RECELL, co's cell harvesting device   urn:newsml:reuters.com:*:nASXbZ54W6
    ** Says RECELL System enables healthcare professionals to
produce Spray-On Skin Cells using patient's own skin for the
treatment of acute thermal burns
    ** Adds that launch of new RECELL System in the United
States will begin in Q2 2022  
    ** Shares hit their highest levels since Feb. 10 
    ** Stock marks its best week since Late-December, gaining
2.7% in value this week 
    ** More than 496,600 shares change hands as compared with
the 30-day average volume of ~311,900 shares  
    ** Stock has fallen 27.2% this year as of last close


 (Reporting by Roushni Nair in Bengluru)
 ((Roushni.Nair@thomsonreuters.com;))